Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in <i>EGFR</i> - and <i>KRAS</i> -Mutant Lung Cancer
Eliminating "persisters" before relapse is crucial for achieving durable treatment efficacy. This study provides a rationale for developing PRMT1-selective inhibitors to target cancer persisters and achieve more durable outcomes in oncogene-targeting therapies.
Authors
- Karl Kumbier (ORCID: https://orcid.org/0000-0001-6521-1173)
- Lani F. Wu (ORCID: https://orcid.org/0000-0002-0052-7537)
- Veronica Steri (ORCID: https://orcid.org/0000-0003-2499-6618)
- Xiaoxiao Sun (ORCID: https://orcid.org/0000-0002-9689-9385)
- Steven J. Altschuler (ORCID: https://orcid.org/0000-0001-9142-0796)
- Savitha Gayathri
Institutions
- University of California, San Francisco (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0389
- Citations
- 1
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- National Cancer Institute